Shanghai-based Zai Lab Limited inks an exclusive license agreement with privately held Entasis Therapeutics for the rights to broad-spectrum intravenous antibiotic ETX2514 in the Asia-Pacific region.

The companies will also partner on developing ETX2514SUL, a fixed-dose combination of ETX2514 and sulbactam, for the treatment of serious multidrug-resistant infections caused by Acinetobacter baumannii. Zai Lab will manage the Phase 3 study conducted in China.

Under the terms of the deal, Entasis will receive $5M upfront, up to $7.6M in near-term milestones, up to $91.0M in additional milestones and royalties on net sales.

Entassis was established in 2015 with startup funding from AstraZeneca and rights to its small molecule anti-infectives portfolio.

Register as Visitor to CPhI China 2018!